| Identification | Back Directory | [Name]
1,3,4-Thiadiazole-2-carboxylic acid, 5-[[4-(aminosulfonyl)benzoyl]amino]-, ethyl ester | [CAS]
2480283-75-6 | [Synonyms]
hCAI/II-IN-2
1,3,4-Thiadiazole-2-carboxylic acid, 5-[[4-(aminosulfonyl)benzoyl]amino]-, ethyl ester | [Molecular Formula]
C12H12N4O5S2 | [MOL File]
2480283-75-6.mol | [Molecular Weight]
356.38 |
| Hazard Information | Back Directory | [Uses]
hCAI/II-IN-2 (compound 2b) is a potent dual hCA I/II inhibitor with Ki values of 40.97, 15.15 and 61.88 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-2 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity[1]. | [in vivo]
| Animal Model: | Male BLAB/c mice[1] | | Dosage: | 400 mg/kg | | Administration: | Oral administration; 14 days. | | Result: | Prolonged the survival time of mice by 21.7% compared with the blank control group. |
| [References]
[1] Yang C, et al. N-Quinary heterocycle-4-sulphamoylbenzamides exert anti-hypoxic effects as dual inhibitors of carbonic anhydrases I/II. Bioorg Chem. 2020 Jul;100:103931. DOI:10.1016/j.bioorg.2020.103931 |
|
|